8-K: Drugs Made In America II CEO Resigns Amid Fund Misuse

Drugs Made In America Acquisition II Corp. announced the resignation of its CEO and Executive Chair following the discovery of significant unauthorized withdrawals and overpayments by its sponsor.

Summary

• The company's sponsor withdrew an aggregate of $1,100,000 from the working capital account between September 26, 2025, and September 30, 2025.
• This amount included $325,000 to repay a working capital note and $208,000 for other offering costs, both exceeding previously advanced amounts.
• An additional $566,269 was identified as an overpayment to the Sponsor.
• Between September 30, 2025, and December 31, 2025, the Sponsor withdrew at least $200,000 more for expenses unrelated to the company.
• The Board directed the Sponsor to return the "Overpayment Amount," but the Sponsor indicated an inability to repay.
• Lynn Stockwell resigned as Chief Executive Officer, Executive Chair of the Board, and Board member, effective February 28, 2026, at the Board's request.
• Roger Bendelac was appointed Chief Executive Officer, effective February 28, 2026.

Sentiment

Score: 1

Explanation: StockSavvy.ai views this as extremely negative due to significant financial misconduct by the sponsor, the inability to recover funds, and the forced resignation of the CEO, indicating severe corporate governance failures.

Positives

• The Board of Directors took decisive action by requesting the CEO's resignation and appointing a new CEO.
• The appointment of Roger Bendelac, with over 30 years of experience in investment banking and corporate advisory, brings seasoned leadership.

Negatives

• Unauthorized withdrawal of at least $1,100,000 from the company's working capital account by the sponsor.
• Repayment of $325,000 for a working capital note and $208,000 for offering costs exceeded amounts previously advanced by the sponsor.
• An overpayment of $566,269 to the sponsor was identified.
• Further withdrawals of at least $200,000 were made by the sponsor for expenses unrelated to the company.
• The sponsor indicated an inability to repay the overpayment amount.
• The Chief Executive Officer and Executive Chair resigned due to the conduct by the sponsor.

Risks

• Significant financial misconduct by the company's sponsor and former management.
• Inability of the sponsor to repay the overpayment amount, potentially leading to a loss of funds for the company.
• Reputational damage and loss of investor confidence due to governance failures.
• Potential for further investigation or legal action related to the unauthorized withdrawals.
• Uncertainty regarding the company's financial health and ability to execute its business plan given the depletion of working capital.

Future Outlook

The Board of Directors intends to consider and approve a compensation arrangement for the new Chief Executive Officer, Roger Bendelac, at a future date, with material terms to be disclosed in a subsequent filing.

Management Comments

• The Board and the Company's Chief Financial Officer learned that Sponsor would not be able to repay the Overpayment Amount back to the Company.
• Lynn Stockwell agreed to tender her resignation as Chief Executive Officer, Executive Chair of the Board and as a Board member.
• Roger Bendelac was appointed to the position of Chief Executive Officer of the Company.

Industry Context

StockSavvy.ai notes that this event highlights persistent corporate governance challenges within the SPAC sector, where sponsor-related party transactions and oversight can sometimes lead to significant financial irregularities. Such incidents can erode investor trust in the SPAC model, emphasizing the critical need for robust independent board oversight and transparent financial controls, especially during the de-SPAC process or prior to target acquisition.

Comparison to Industry Standards

• The unauthorized withdrawals and inability of the sponsor to repay funds fall significantly below standard corporate governance practices for publicly traded companies, including SPACs.
• Compared to well-governed SPACs like those sponsored by established financial institutions (e.g., Goldman Sachs-backed SPACs or TPG Pace Group), the internal controls and oversight at Drugs Made In America Acquisition II Corp. appear to have been severely deficient.
• The immediate resignation of the CEO and Executive Chair following the discovery of financial misconduct is a necessary, though reactive, step, contrasting with proactive governance measures seen in industry leaders.
• The appointment of an experienced professional like Roger Bendelac is a positive step towards remediation, but the underlying issues represent a stark deviation from the fiduciary responsibilities expected of a public company's board and management.

Management Changes

Corporate Governance

Related Party Transactions

• Withdrawal of $1,100,000 by the sponsor from the company's working capital account, including repayments to the sponsor that exceeded previously advanced amounts.
• Identification of a $566,269 overpayment to the sponsor.
• Additional withdrawals of at least $200,000 by the sponsor for expenses unrelated to the company.
• The sponsor's inability to repay the overpayment amount.

Stakeholder Impact

• Shareholders: Significant negative impact due to potential loss of company funds, erosion of trust, and uncertainty regarding future prospects and share value.
• Employees: Potential for decreased morale and uncertainty regarding the company's stability and future direction.
• Creditors: Increased risk perception due to financial irregularities and governance issues, potentially impacting future credit terms.
• Regulatory Authorities: Likely increased scrutiny from the SEC due to the disclosed financial misconduct and corporate governance failures.

Next Steps

• The Board of Directors will consider and approve a compensation arrangement for the new Chief Executive Officer, Roger Bendelac.
• Material terms of Mr. Bendelac's compensation will be disclosed in a subsequent filing.

Key Dates

Recommendation

The filing reveals severe corporate governance failures, including significant unauthorized withdrawals and overpayments by the company's sponsor, and the sponsor's inability to repay these funds. The forced resignation of the CEO and Executive Chair underscores the gravity of the situation. These issues indicate a high risk of financial loss, reputational damage, and potential regulatory action, making the stock a strong sell for investors.

Keywords

SPAC, corporate governance, management change, financial misconduct, CEO resignation, working capital, overpayment, SEC filing, Drugs Made In America Acquisition II Corp., DMIIU